Comparing human normal immunoglobulin (iv) and a drug combination to prevent infections in adults with B-cell acute lymphoblastic leukemia or B-cell lymphoma treated with CAR-T cells

Registered drugNo placebo

Comparing human normal immunoglobulin (iv) and a drug combination to prevent infections in adults with B-cell acute lymphoblastic leukemia or B-cell lymphoma treated with CAR-T cells

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Amoxicillin Sodium
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Non-small cell lung cancer

Not yet recruiting

A study to evaluate the safety and effectiveness of petosemtamab and pembrolizumab in adults with non-small cell lung cancer

Registered drugNo placebo

A study to evaluate the safety and effectiveness of petosemtamab and pembrolizumab in adults with non-small cell lung cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Merus B.V.

Contact Research Centre

Plasma cell myeloma

Not yet recruiting

A study of belantamab mafodotin and mezigdomide in patients with relapsed multiple myeloma who have previously received CAR-T cell therapy or bispecific antibodies

InvestigationalNo placebo

A study of belantamab mafodotin and mezigdomide in patients with relapsed multiple myeloma who have previously received CAR-T cell therapy or bispecific antibodies

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Belantamab Mafodotin
Sponsor:Centre Hospitalier Universitaire De Saint Etienne

Contact Research Centre

Colitis ulcerative

Not yet recruiting

A study comparing vedolizumab, filgotinib, ustekinumab, and infliximab to maintain remission in patients with ulcerative colitis

Registered drugNo placebo

A study comparing vedolizumab, filgotinib, ustekinumab, and infliximab to maintain remission in patients with ulcerative colitis

Registered drugNo placebo

France

Participants:18–64 years
Substances:Filgotinib
Sponsor:University Hospital Of Clermont-Ferrand

Contact Research Centre

Ischaemic stroke

Not yet recruiting

Comparing tenecteplase and mechanical clot removal versus mechanical clot removal alone for adults with a large ischemic stroke

Registered drugNo placebo

Comparing tenecteplase and mechanical clot removal versus mechanical clot removal alone for adults with a large ischemic stroke

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Tenecteplase
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Primary bilateral macronodular adrenal hyperplasia

Not yet recruiting

Study of the effect of metyrapone in patients with mild Cushing syndrome caused by primary bilateral macronodular adrenal hyperplasia

Registered drug

Study of the effect of metyrapone in patients with mild Cushing syndrome caused by primary bilateral macronodular adrenal hyperplasia

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Metyrapone
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Plasma cell myeloma

Not yet recruiting

A study of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in adults with newly diagnosed multiple myeloma not eligible for transplant

Registered drugNo placebo

A study of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in adults with newly diagnosed multiple myeloma not eligible for transplant

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Daratumumab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Atrial fibrillation

Not yet recruiting

A study on the effect of hydrogen inhalation therapy to prevent the early return of atrial fibrillation in patients after heart ablation treatment.

InvestigationalNo placebo

A study on the effect of hydrogen inhalation therapy to prevent the early return of atrial fibrillation in patients after heart ablation treatment.

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Hydrogen
Sponsor:Centre Hospitalier Universitaire Grenoble Alpes

Contact Research Centre

Neuroendocrine carcinoma metastatic

Not yet recruiting

A study of irinotecan, fluorouracil, calcium folinate, zimberelimab, and domvanalimab for patients with metastatic gastro-enteropancreatic neuroendocrine carcinoma.

Registered drugNo placebo

A study of irinotecan, fluorouracil, calcium folinate, zimberelimab, and domvanalimab for patients with metastatic gastro-enteropancreatic neuroendocrine carcinoma.

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Hospices Civils De Lyon

Contact Research Centre

Mechanical ventilation+1

Not yet recruiting

Study of dexmedetomidine versus placebo to reduce opioid use in premature babies requiring mechanical ventilation for respiratory distress

Registered drug

Study of dexmedetomidine versus placebo to reduce opioid use in premature babies requiring mechanical ventilation for respiratory distress

Registered drug

France

Participants:0–17 years
Substances:Dexmedetomidine
Sponsor:Centre Hospitalier Intercommunal Creteil

Contact Research Centre

Pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis

Investigational

A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis

Investigational

France

Participants:18–64 years · 65+ years
Substances:Admilparant
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Chambery

What the registry says about research in the country

01 Hematologic Oncology

Innovative research focusing on multiple myeloma and various lymphomas, evaluating novel therapeutic combinations and treatment strategies.

Multiple Myeloma Treatments
Follicular Lymphoma Studies
Diffuse Large B-cell Lymphoma Research

Advanced trials exploring combinations of immunotherapy and targeted treatments for blood cancers.

02 Lung Cancer Research

Studies examining innovative treatments for non-small cell lung cancer, particularly focusing on immunotherapy approaches.

Immunotherapy Combinations
Elderly Patient Treatment Options
Novel Therapeutic Strategies

Emphasis on improving treatment outcomes through targeted and combination therapies.

03 Preventive Medicine

Research on pneumococcal vaccines and preventive treatments, including studies in specialized patient populations.

Vaccine Immunogenicity
Safety Studies
High-Risk Patient Groups

Focus on vaccine effectiveness during acute illness conditions.

04 Breast Cancer Studies

Clinical trials examining treatments for hormone-sensitive breast cancer, including targeted therapies and hormone treatment optimization.

Hormone Therapy Duration
Metastatic Disease Management
Biomarker Studies

Investigation of personalized treatment approaches based on molecular markers.

Back to France All countries